The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-13 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
His company teamed up with the Orchestre de la Suisse Romande (OSR) to record the world's first holographic symphonic performance presented at Artgenève 2024. In 2025, Orunesu's company, Cybel’Art, developed and launched Virtual Hall, a virtual reality application designed for symphonic performances, belonging to Orchestre de la Suisse Romande. The platform enables users to view concerts from various on-stage perspectives using 360-degree immersive video. Orunesu is credited as the architect and inventor of the technology, which integrates multi-camera setups and synchronized audio-visual processing. Virtual Hall was first presented at Artgenève 2025. In October 2025, Orunesu used his Virtual Hall immersive technology to document a performance of Beethoven’s Ninth Symphony held to mark the 750th anniversary of Lausanne Cathedral. The project used a capture setup with 11 360-degree cameras and 33 microphones. The performance, titled “The Ninth Symphony in Nine Luminous Scenes,” was conceived by Renato Häusler (Kalalumen) and involved more than 270 participants, including musicians, choir members, and lighting technicians. In 2026, Pierluigi Christophe Orunesu, founder of Swiss ArtTech company Cybel'Art SA, collaborated with legendary Tolkien illustrator John Howe at La Tour du Fantastique in Neuchâtel, Switzerland.
They allow a continuous infusion of small amounts of insulin to be delivered through the skin around the clock. They also have the ability to give bolus doses when a person eats or has elevated blood glucose levels. They are also capable to being used in conjunction with continuous glucose monitors for optimal glucose management. This is very similar to how the pancreas works, but these pumps lack a continuous "feed-back" mechanism. Thus, the user is still at risk of giving too much or too little insulin unless blood glucose measurements are made.
This end proves to be both more thermodynamically favored for the addition of G-actin and kinetically dynamic as well. Simultaneously, older G-actin monomers "fall off" of the pointed end of the microfilament. At the "pointed end" of the F-actin polymer, actin monomers are bound to ADP, which dissociates more readily and rapidly than ATP-bound actin, which is found at the "barbed end" of the polymer. Thus, in environments with high concentrations of free actin subunits, filamentous growth at the "barbed end" remains greater than that of the "pointed end". This "tread-milling", essentially exists as a simplified explanation of the actin remodeling process.
=== Properties === Minoxidil is an odorless, white to off-white, crystalline powder (crystals from methanol-acetonitrile). When heated to decomposition it emits toxic fumes of nitrogen oxides. It decomposes at 259-261 °C. Its solubility (mg/ml) is propylene glycol 75, methanol 44, ethanol 29, 2-propanol 6.7, dimethylsulfoxide 6.5, water 2.2, chloroform 0.5, acetone <0.5, ethyl acetate <0.5, diethyl ether <0.5, benzene <0.5, acetonitrile <0.5. The pKa of minoxidil is 4.61.
Sources: en.wikipedia.org
One visit to Afghanistan, Angola, Argentina, Belarus, Benin, Cameroon, Canada, Chad, Chile, Colombia, Comoros, Cuba, Cyprus, Czech Republic, Democratic Republic of the Congo, Ethiopia, Georgia, Guinea, Haiti, Iceland, Indonesia, Ireland, Ivory Coast (Côte d'Ivoire), Kazakhstan, Laos, Latvia, Lithuania, Luxembourg, Madagascar, Malaysia, Monaco, Niger, Norway, Palestine, Peru, Philippines, Romania, Singapore, Slovenia, South Korea, Turkey, Ukraine, Uruguay and Vietnam. Two visits to Algeria, Armenia, Australia, Azerbaijan, Egypt, India, Iraq, Israel, Japan, Jordan, Lebanon, Mexico, Netherlands, Nigeria, Portugal, Qatar, Senegal, South Africa, United Arab Emirates and Vatican City. Three visits to Brazil, the Central African Republic, China, Greece, Mali, Morocco, Slovakia and Tunisia. Four visits to Malta and Switzerland. Five visits to Russia, Spain and Saudi Arabia. Six visits to Poland. Seven visits to the United Kingdom. Eight visits to Italy. Ten visits to the United States. Twenty-two visits to Germany. Forty-two visits to Belgium.
== Parameters == The parameters included in the semen analysis can be divided in macroscopic (liquefaction, appearance, viscosity, volume and pH) and microscopic (motility, morphology, vitality, concentration, sperm count, sperm aggregation, sperm agglutination, and presence of round cells or leukocytes). The main three parameters of the spermiogram are the concentration of the spermatozoa in the semen, the motility and the morphology of them. This analysis is important to analyse fertility, but even in a perfectly fertile man is very difficult to find normal spermatozoa. For the average fertile man, only 4% of their spermatozoa are normal in every parameter, while 96% are abnormal in at least one of them.
By the early 2000s this severe sampling rate limitation had motivated users of FAB-MS for mineral isotope analysis to switch to conventional inorganic mass spectrometers, usually ICP-MS which also exhibited improved affordability and isotope ratio analysis performance by that time.
Sources: en.wikipedia.org
==== NIH Toolbox ==== In September 2006, the NIH Blueprint for Neuroscience Research started a contract for the NIH Toolbox for the Assessment of Neurological and Behavioral Function to develop a set of state-of-the-art measurement tools to enhance collection of data in large cohort studies. More than 250 scientists from almost 100 academic institutions contributed to its development. In September 2012, the NIH Toolbox was rolled out to the research community. NIH Toolbox assessments are based, where possible, on Item Response Theory and adapted for testing by computer.
Nucleotides are made from amino acids, carbon dioxide and formic acid in pathways that require large amounts of metabolic energy. Consequently, most organisms have efficient systems to salvage preformed nucleotides. Purines are synthesized as nucleosides (bases attached to ribose). Both adenine and guanine are made from the precursor nucleoside inosine monophosphate, which is synthesized using atoms from the amino acids glycine, glutamine, and aspartic acid, as well as formate transferred from the coenzyme tetrahydrofolate. Pyrimidines, on the other hand, are synthesized from the base orotate, which is formed from glutamine and aspartate.
=== Os cordis === In some animals, the fibrous trigone can undergo increasing mineralization with age, leading to the formation of a significant os cordis (heart bone), or two (os cordis sinistrum and os cordis dextrum, the latter being the larger one). The os cordis is thought to serve mechanical functions. In humans, two paired trigones (left and right) are seen in this essential view of anatomy. As a surgical purchase point, the Trigones risk much in AV propagation. It has been known since Classical times in deer and oxen and was thought to have medicinal properties and mystical properties. It is occasionally observed in many other artiodactyls including goats, sheep, giraffes, camels, water buffalo, and antelopes but also in carnivorans such as otters, dogs, cats, and sea lions and in the horse. It has also been discovered in chimpanzees, the first known great ape to have an os cordis; it has subsequently been reported in a human, though its etiology is unknown. Against the opinion of his time, Galen wrote that the os cordis was also found in elephants. While it is unclear if Galen actually observed the bone, it has since been identified in Asian elephants.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.